WO2007137386A1 - Compositions and methods for the cure of hiv/aids - Google Patents

Compositions and methods for the cure of hiv/aids Download PDF

Info

Publication number
WO2007137386A1
WO2007137386A1 PCT/CA2006/000867 CA2006000867W WO2007137386A1 WO 2007137386 A1 WO2007137386 A1 WO 2007137386A1 CA 2006000867 W CA2006000867 W CA 2006000867W WO 2007137386 A1 WO2007137386 A1 WO 2007137386A1
Authority
WO
WIPO (PCT)
Prior art keywords
neem
water
protein
components
powdered
Prior art date
Application number
PCT/CA2006/000867
Other languages
French (fr)
Inventor
Rajesh Radhakrishnan
Original Assignee
Devarajan Anitha
Rajesh Radhakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Devarajan Anitha, Rajesh Radhakrishnan filed Critical Devarajan Anitha
Priority to PCT/CA2006/000867 priority Critical patent/WO2007137386A1/en
Priority to CNA2006800229194A priority patent/CN101389344A/en
Priority to PCT/CA2006/001970 priority patent/WO2007137389A1/en
Priority to US11/713,817 priority patent/US20070275085A1/en
Priority to CA002580982A priority patent/CA2580982A1/en
Priority to GBGB0712015.7A priority patent/GB0712015D0/en
Publication of WO2007137386A1 publication Critical patent/WO2007137386A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to the treatment of persons with human immunodeficiency virus (HIV) infection.
  • HIV human immunodeficiency virus
  • the Neem tree (Azadirachta Indica) is a plant that grows wild in many parts of the world where the climate is warm, notably, India and Africa. Throughout India and Africa, different parts of the Neem tree, inclusive of leaves, bark, flower and seed, are employed as remedies for various human ailments.
  • HIV human immunodeficiency virus
  • Udeinya teaches the collection of fresh green leaves from mature trees. The leaves are oven-dried, ground to a coarse powder and extracted using a mixture of acetone and distilled water. The solvent is removed through a process of rotor- evaporation. Precipitates on the side of the rotor flask are removed with acetone. The acetone solution is allowed to evaporate at room temperature, leaving a substance designated as IRAB. IRAB is suggested to be useful to inhibit development of the HIV virus when mixed with a physiologically acceptable carrier.
  • Udeinya fails to disclose dosage regimes or levels, and fails to disclose a useful carrier.
  • a pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection forms one aspect of the invention.
  • This composition comprises effective amounts of: components obtained from Neem (Azadirachta Indica); and a protein supplement.
  • a pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection forms another aspect of the invention.
  • This composition is produced by: contacting powdered Neem (Azadirachta Indica) with water to allow said water to extract components from said Neem powder to produce an aqueous extract; and mixing the aqueous extract with a protein supplement.
  • a method for treating a patient with human immunodeficiency virus infection forms yet another aspect of the invention.
  • This method comprises the step of orally administering to said patient an effective amount of components of Neem in combination with a protein supplement.
  • FIGURE 1 is a photograph demonstrating the effects of treatment.
  • the volume of the slurry is reduced, through boiling, to 750 ml., to extract components from the powdered Neem.
  • the reduced slurry is filtered through cloth to produce an aqueous extract containing components extracted from the Neem powder and to also produce a residue of depleted Neem powder.
  • the aqueous extract is mixed with 112.5 grams of a commercially available protein drink mix powder to produce a pharmaceutical composition in drink form.
  • a serving of the drink is ingested by a patient 5 times daily, 5-6 days per week, such that the total amount of protein ingested by the patient is about 1 gram/kilogram body weight/day.
  • the protein drink mix powder is of the type including about 89 wt. % cross-flow microfiltered Whey Protein Isolate, with the remaining 11 wt. % comprising Corosolic Acid, Protease I, Protease II and Piperine Extract.
  • each serving is prepared by mixing 150 ml aqueous extract with 22.5 grams protein drink mix powder (which contains approx. 20 grams protein).
  • Treatment in this manner continues for at least one year. Thereafter, once blood HIV viral counts have fallen below 50 /ml, treatment continues, but the amount of Neem in each serving is cut in half.
  • Figure 1 is a photograph of the skin of a male patient in the course of treatment.
  • the visible tissue discoloration within encircled area 20 is evidence of the composition at work eradicating the HIV virus deep within the muscle tissues of the patient.
  • the components extracted from Neem are adapted to facilitate the production of antibodies against the HIV virus.
  • the primary constituent of antibodies is protein
  • this production is supported by the protein supplement, which makes protein readily available in the body for antibody production.
  • the drink itself could also be dehydrated and powdered, for subsequent rehydration and use at a later date.
  • the protein supplement and Neem components could also be ingested separately. Whereas Whey Protein Isolate is taught for use as the protein supplement, other protein sources could be utilized. Compounds used by the body in protein formation, i.e. amino acids, could also be utilized, and are intended to fall within the meaning of the term "protein supplements" as utilized herein . Accordingly, the invention should be understood as limited only by the claims appended hereto, purposively construed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection is disclosed. The composition comprises effective amounts of: components obtained from Neem (Azadirachta Indica); and a protein supplement. This composition can be produced by: contacting powdered Neem with water to allow said water to extract components from said Neem powder to produce an aqueous extract; and mixing the aqueous extract with a protein supplement to form a drink. A method for treating a patient with human immunodeficiency virus infection is also disclosed. This method can comprise the step of orally administering to said patient the drink.

Description

COMPOSITIONS AND METHODS FOR THE CURE OF HIV/ AIDS
FIELD OF THE INVENTION
The present invention relates to the treatment of persons with human immunodeficiency virus (HIV) infection.
BACKGROUND OF THE INVENTION
The Neem tree (Azadirachta Indica) is a plant that grows wild in many parts of the world where the climate is warm, notably, India and Africa. Throughout India and Africa, different parts of the Neem tree, inclusive of leaves, bark, flower and seed, are employed as remedies for various human ailments.
The prior art suggests the utilization of compounds derived from the Neem tree for the treatment of persons with human immunodeficiency virus (HIV) infection, which is known to be a difficult infection to treat, due in part to the ability of the virus to position itself deep within the muscle tissues of those infected.
For example, in US 5,370,873 (Udeinya), issued December 6, 1994, it is taught to produce a pharmaceutical preparation based on Neem leaves. Udeinya teaches the collection of fresh green leaves from mature trees. The leaves are oven-dried, ground to a coarse powder and extracted using a mixture of acetone and distilled water. The solvent is removed through a process of rotor- evaporation. Precipitates on the side of the rotor flask are removed with acetone. The acetone solution is allowed to evaporate at room temperature, leaving a substance designated as IRAB. IRAB is suggested to be useful to inhibit development of the HIV virus when mixed with a physiologically acceptable carrier. However, Udeinya fails to disclose dosage regimes or levels, and fails to disclose a useful carrier. SUMMARY OF THE INVENTION
A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection forms one aspect of the invention. This composition comprises effective amounts of: components obtained from Neem (Azadirachta Indica); and a protein supplement.
A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection forms another aspect of the invention. This composition is produced by: contacting powdered Neem (Azadirachta Indica) with water to allow said water to extract components from said Neem powder to produce an aqueous extract; and mixing the aqueous extract with a protein supplement.
A method for treating a patient with human immunodeficiency virus infection forms yet another aspect of the invention. This method comprises the step of orally administering to said patient an effective amount of components of Neem in combination with a protein supplement.
Other advantages, features and characteristics of the present invention will become more apparent upon consideration of the following detailed description and the appended claims with reference to the photograph, the latter being briefly described hereinbelow.
BRIEF DESCRIPTION OF THE PHOTOGRAPH
FIGURE 1 is a photograph demonstrating the effects of treatment. DETAILED DESCRIPTION
A preferred method for the treatment of HIV infection is hereinafter described.
In this method, 1.25 litres of potable water is mixed with 20 grams of commercially available powdered Neem, of the type derived from bark, leaves, flowers and seeds, to form a slurry.
The volume of the slurry is reduced, through boiling, to 750 ml., to extract components from the powdered Neem.
The reduced slurry is filtered through cloth to produce an aqueous extract containing components extracted from the Neem powder and to also produce a residue of depleted Neem powder.
The aqueous extract is mixed with 112.5 grams of a commercially available protein drink mix powder to produce a pharmaceutical composition in drink form. A serving of the drink is ingested by a patient 5 times daily, 5-6 days per week, such that the total amount of protein ingested by the patient is about 1 gram/kilogram body weight/day. In this preferred method, the protein drink mix powder is of the type including about 89 wt. % cross-flow microfiltered Whey Protein Isolate, with the remaining 11 wt. % comprising Corosolic Acid, Protease I, Protease II and Piperine Extract. For example, in the case of a 100 kg patient, each serving is prepared by mixing 150 ml aqueous extract with 22.5 grams protein drink mix powder (which contains approx. 20 grams protein).
In the event of extreme fatigue, treatment is arrested for 2-3 days and then resumed.
Treatment in this manner continues for at least one year. Thereafter, once blood HIV viral counts have fallen below 50 /ml, treatment continues, but the amount of Neem in each serving is cut in half.
Thus, in the case of the preferred method described hereinbefore, 10 grams of powdered Neem, rather than 20 grams, is used to form the slurry.
The treatment continues until the HIV infection is eradicated, which may take 2- 3 years.
Figure 1 is a photograph of the skin of a male patient in the course of treatment. The visible tissue discoloration within encircled area 20 is evidence of the composition at work eradicating the HIV virus deep within the muscle tissues of the patient.
Without intending to be bound by theory, it is believed that the components extracted from Neem are adapted to facilitate the production of antibodies against the HIV virus. As the primary constituent of antibodies is protein, this production is supported by the protein supplement, which makes protein readily available in the body for antibody production.
While but a single embodiment of the present invention has been herein shown and described, it will be understood that various changes may be made. For example, whereas the use of a commercially available protein drink mix supplement is taught, other sources of protein could be utilized. Simple Whey protein isolate could, for example, be utilized in the place of the protein drink mix supplement. As well, whereas the water used to extract components from powdered Neem is described to be used to form the basis of a drink, the water could equally be evaporated from the aqueous extract, to leave a Neem residue which could be mixed with protein and formed into a tablet, capsule or the like, for daily ingestion, or formed into a powder for subsequent mixture with water to form the drink. The drink itself could also be dehydrated and powdered, for subsequent rehydration and use at a later date. The protein supplement and Neem components could also be ingested separately. Whereas Whey Protein Isolate is taught for use as the protein supplement, other protein sources could be utilized. Compounds used by the body in protein formation, i.e. amino acids, could also be utilized, and are intended to fall within the meaning of the term "protein supplements" as utilized herein . Accordingly, the invention should be understood as limited only by the claims appended hereto, purposively construed.

Claims

1. A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection, said composition comprising effective amounts of:
components obtained from Neem (Azadirachta Indica); and
a protein supplement.
2. A pharmaceutical composition according to claim 1, wherein the components are obtained by extracting powdered Neem with water.
3. A pharmaceutical composition according to claim 1, wherein the protein supplement comprises Whey Protein Isolate.
4. A pharmaceutical composition according to claim 1, wherein the components are obtained from the bark, seed, flower and leaf of Neem.
5. A pharmaceutical composition according to claim 1 in the form of a drink.
6. A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection, said composition being produced by:
contacting powdered Neem (Azadirachta Indica) with water to allow said water to extract components from said Neem powder to produce an aqueous extract; and
mixing the aqueous extract with a protein supplement.
7. A composition according to claim 6, wherein the powdered Neem is a powder of Neem bark, seed, flower and leaf.
8. A composition according to claim 6, wherein the contacting step comprising boiling the water.
9. A composition according to claim 8, wherein about 40% of the water volume is evaporated during the contacting step.
10. A composition according to claim 6, wherein the water is contacted with the powdered Neem and thereafter filtered to produce the aqueous extract and a residue of depleted Neem powder.
11. A composition according to claim 6, wherein the powdered Neem and water are provided in the weight ratio of about 20: 1250 for the contacting step.
12. A composition according to claim 6, wherein the aqueous extract and the protein supplement are mixed in a weight ratio of about 1500:225 in the mixing step.
13. A method for treating a patient with human immunodeficiency virus infection, said method comprising the step of orally administering to said patient an effective amount of components of Neem in combination with a protein supplement.
14. A method according to claim 13, wherein the effective amount of components of Neem and the protein supplement are provided in the form of a drink produced by:
contacting powdered Neem (Azadirachta Indica) with water to allow said water to extract components from said Neem powder to produce an aqueous extract; and
mixing the aqueous extract with a protein supplement.
15. A method according to claim 14, wherein the powdered Neem is a powder of Neem bark, seed, flower and leaf.
16. A method according to claim 14, wherein the contacting step comprising boiling the water.
17. A method according to claim 14, wherein the water is contacted with the powdered Neem and thereafter filtered to produce the aqueous extract and a residue of depleted Neem powder.
18. A method according to claim 14, wherein the aqueous extract and the protein supplement are mixed in a weight ratio of about 1500:225 in the mixing step.
9. A method according to claim 14, wherein, in an initial treatment step,
in the drink, the weight ratio of:
the grams of powdered Neem from which the components of Neem are derived ;
to
protein
is about 1 :5 and
the drink is orally administered to the patient
several times daily, such that the aggregate amount of the protein administered to the patient each day is 1 gram per kilogram body weight; and
for at least one year, and until blood viral counts fall below 50 per ml.
0. A method according to claim 19, wherein, after the initial treatment step,
in the drink, the weight ratio of:
the grams of powdered Neem from which the components of Neem are derived ;
to
protein
is about 1: 10 and
the drink is orally administered several times daily to the patient, such that the aggregate amount of the protein administered to the patient each day is 1 gram per kilogram body weight.
PCT/CA2006/000867 2006-05-26 2006-05-26 Compositions and methods for the cure of hiv/aids WO2007137386A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/CA2006/000867 WO2007137386A1 (en) 2006-05-26 2006-05-26 Compositions and methods for the cure of hiv/aids
CNA2006800229194A CN101389344A (en) 2006-05-26 2006-05-26 Synthesized medicament and method for treating HIV
PCT/CA2006/001970 WO2007137389A1 (en) 2006-05-26 2006-12-04 Use of compounds obtained from the neem tree (azadirachta indica) for the treatment of hiv/aids
US11/713,817 US20070275085A1 (en) 2006-05-26 2007-03-05 Compositions and methods for the cure of HIV / AIDS
CA002580982A CA2580982A1 (en) 2006-05-26 2007-03-19 Compositions and methods for the cure of hiv/aids
GBGB0712015.7A GB0712015D0 (en) 2006-05-26 2007-06-14 No title

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2006/000867 WO2007137386A1 (en) 2006-05-26 2006-05-26 Compositions and methods for the cure of hiv/aids

Publications (1)

Publication Number Publication Date
WO2007137386A1 true WO2007137386A1 (en) 2007-12-06

Family

ID=38352646

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA2006/000867 WO2007137386A1 (en) 2006-05-26 2006-05-26 Compositions and methods for the cure of hiv/aids
PCT/CA2006/001970 WO2007137389A1 (en) 2006-05-26 2006-12-04 Use of compounds obtained from the neem tree (azadirachta indica) for the treatment of hiv/aids

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001970 WO2007137389A1 (en) 2006-05-26 2006-12-04 Use of compounds obtained from the neem tree (azadirachta indica) for the treatment of hiv/aids

Country Status (3)

Country Link
CN (1) CN101389344A (en)
GB (1) GB0712015D0 (en)
WO (2) WO2007137386A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291647B2 (en) 2018-08-30 2022-04-05 Nisarga Biotech Private Limited Process for preparation of CO2 extract of Azadirachta indica and herbal compositions thereof for treatment of cancers
EP4342482A1 (en) 2022-09-23 2024-03-27 Laurenz Vorderwülbecke Neem tree leaves extract

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115709A (en) * 1980-02-20 1981-09-11 Koji Mitsuo Material utilizable as drug, food or cosmetic
US5370873A (en) * 1992-09-11 1994-12-06 Udeinya; Iroka J. Therapeutic compounds derived from the neem tree
WO2005030232A2 (en) * 2003-07-14 2005-04-07 Shambabu Ayare Herbal compositions for effective treatment of aids, preparation thereof and method for treatment of aids patients
WO2006008761A2 (en) * 2004-07-23 2006-01-26 A K Raja Anti retroviral herbal formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115709A (en) * 1980-02-20 1981-09-11 Koji Mitsuo Material utilizable as drug, food or cosmetic
US5370873A (en) * 1992-09-11 1994-12-06 Udeinya; Iroka J. Therapeutic compounds derived from the neem tree
WO2005030232A2 (en) * 2003-07-14 2005-04-07 Shambabu Ayare Herbal compositions for effective treatment of aids, preparation thereof and method for treatment of aids patients
WO2006008761A2 (en) * 2004-07-23 2006-01-26 A K Raja Anti retroviral herbal formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EL ATTA H.A. ET AL.: "Comparative effects of some botanicals for the control of the seed weevil Caryedon serratus Olivier (Col., Bruchidae)", J. APPL. ENT., vol. 126, 2002, pages 577 - 582, XP008090865 *
HUSSEIN G. ET AL.: "Inhibitory effects of Sudanese plant extracts on HIV-1 replication and HIV-1 protease", PHYTOTHERAPY RESEARCH, vol. 13, 1999, pages 31 - 36, XP008090982 *
UDEINYA I.J. ET AL.: "An antimalarial extract from neem leaves is antiretroviral", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, vol. 98, July 2004 (2004-07-01), pages 435 - 437, XP008091999 *

Also Published As

Publication number Publication date
CN101389344A (en) 2009-03-18
GB0712015D0 (en) 2007-08-01
WO2007137389A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
Noor et al. The hypoglycaemic and insulinotropic activity of Tinospora crispa: studies with human and rat islets and HIT-T15 B cells
US20070292543A1 (en) Extracts From Roots And/Or Shoots Of Asparagus Officinalis L., Their Preparation And Their Use
CN102973610A (en) Method for preparing phthisic adjuvant with extractum of Periplaneta americana
KR100755983B1 (en) Composition for stimulating hair growth and preventing depilation containing bamboo extract
JP4780899B2 (en) Method for producing a preparation having an effect on allergic symptoms
WO2007137386A1 (en) Compositions and methods for the cure of hiv/aids
US20070275085A1 (en) Compositions and methods for the cure of HIV / AIDS
RU2580282C1 (en) Agent for preventing and treating urolithiasis
RU2006109838A (en) METHOD FOR PREVENTION AND TREATMENT OF COMPLICATIONS IN RADIATION AND CHEMOTHERAPY OF CANCER OF VARIOUS LOCALIZATION
RU2370274C1 (en) Bioactive veterinary drug and method of non-specific resistanse improval for calves using drug
KR100289990B1 (en) Herbal composition for promoting growth hormone secretion and growth hormone secretagogue prepared using the same
JPH01238532A (en) Antiinfectant
RU2303993C1 (en) Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases
CN102125129A (en) Health care tea
RU2456011C1 (en) Preparation flavosuccine for treating and preventing renal and urinary diseases
JP2011012021A (en) Blood sugar-controlling composition
CN101199826A (en) Patch of carsick-prevention containing hindu datura flower component
JP4135933B2 (en) Antitussive and preparation method thereof
RU2371192C1 (en) Medicine stimulating protective powers of organism, and method of correction of secondary immunodeficiencies with its application
KR100522532B1 (en) Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia
RU2382652C1 (en) Therapeutic preparation for young growth of agricultural animals and method for prevention and treatment of gastrointestinal diseases of calves with its application
RU2224536C1 (en) Medicinal agent for treatment of pancreatitis and diabetes mellitus
US20230102810A1 (en) The use of unripened green mangifera indica as a natural preparation to treat sars-cov-2
RU2423996C1 (en) Method of phytopreparation therapy of gastrointestinal diseases in calves
US7306816B1 (en) Medicinal plant compositions of matter and method of preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680022919.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 893/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 0712015.7

Country of ref document: GB

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06741576

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A OF 17.04.2009

122 Ep: pct application non-entry in european phase

Ref document number: 06741576

Country of ref document: EP

Kind code of ref document: A1